Amersham gets US approval for Myoview
This article was originally published in Clinica
Amersham plans to launch its heart imaging agent, Myoview, in the US in March. Recent FDA approval gives Amersham access to the largest market for cardiology imaging. The North American market accounts for £140 million ($213 million) of a £250 million world market. The Tc-99m tetrafosmin kit will be distributed through Medi-Physics, the company's wholly-owned US subsidiary which owns 120 radiopharmacies.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.